CAS NO: | 1155419-89-8 |
包装 | 价格(元) |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | BI 224436 is a novelHIV-1noncatalytic site integrase inhibitor withEC50values of less than 15 nM against differentHIV-1laboratory strains. | ||||||||||||||||
IC50& Target | EC50: 15 nM (HIV-1)[1] | ||||||||||||||||
体外研究 (In Vitro) | BI 224436 has cellular cytotoxicity of more than 90 μM. BI 224436 has a low, 2.1-fold decrease in antiviral potency in the presence of 50% human serum. BI 224436 retains full antiviral activity against recombinant viruses encoding INSTI resistance substitutions N155S, Q148H, and E92Q. BI 224436 displays an additive effect in combination with most approved antiretrovirals, including INSTIs. BI 224436 has drug-likein vitroabsorption, distribution, metabolism, and excretion (ADME) properties, including Caco-2 cell permeability, solubility, and low cytochrome P450 inhibition[1]. | ||||||||||||||||
体内研究 (In Vivo) | BI 224436 exhibits excellent pharmacokinetic profiles in rat (clearance as a percentage of hepatic flow [CL], 0.7%; bioavailability [F], 54%), monkey (CL, 23%; F, 82%), and dog (CL, 8%; F, 81%)[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 442.51 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C27H26N2O4 | ||||||||||||||||
CAS 号 | 1155419-89-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
*该产品在溶液状态不稳定,建议您现用现配,即刻使用。 | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(112.99 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液;该产品在溶液状态不稳定,建议您现用现配,即刻使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|